Labcorp Holdings Inc.
09/22/2026 | Press release | Distributed by Public on 09/22/2026 14:44
Regulation FD Disclosure (Form 8-K)
| Item 7.01. | Regulation FD Disclosure. |
On September 21, 2026, the Centers for Medicare & Medicaid Services ("CMS") released preliminary Clinical Laboratory Fee Schedule payment rates applicable from 2027 through 2029 pursuant to the Protecting Access to Medicare Act ("PAMA"). Labcorp Holdings Inc. (the "Company") believes the payment rates are based on data that is not fully representative of the broader commercial laboratory market and would impose steep annual payment cuts that threaten patient access to laboratory services. Therefore, the Company continues to support the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services ("RESULTS") Act, a bipartisan solution that would ensure the U.S. has a sustainable and innovative laboratory system.
The Company previously considered the anticipated continuation of PAMA-related reimbursement pressure in developing the 2026-2029 long-term outlook announced at its Investor Day on September 10, 2026, and the Company is now reaffirming that outlook, which is:
•Compound annual revenue growth between 5% and 8%.
•Adjusted operating margin expansion between 75 and 150 basis points by the end of 2029.
•Compound annual adjusted EPS growth between 8.5% and 11.5%.
•Compound annual free cash flow growth in line with adjusted earnings growth.
The Company is continuing to evaluate the CMS payment rates and expects to provide additional information regarding the impact of the CMS payment rates on its 2027 financial guidance when that guidance is announced in February 2027.
Other than the 2026-2029 long-term outlook referenced above, all of the information included in the Company's September 10, 2026, Investor Day presentation is presented as of the dates indicated.
The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and such information shall not be deemed incorporated by reference into any filing or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Use of Adjusted Measures
The Company has provided in this Current Report "adjusted" financial information that has not been prepared in accordance with GAAP, including with respect to adjusted EPS growth, adjusted operating margin expansion, and free cash flow. The Company is not able to provide reconciliations of these adjusted measures on a forward-looking basis because it is unable to predict, without unreasonable effort, certain components thereof. As such, any associated estimate and its impact on these measures could vary materially, and the Company cannot address the probable significance of unavailable information. The Company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the Company's operational performance. The Company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the Company's financial results with the financial results of other companies.
Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures prepared in accordance with GAAP, and these adjusted measures may be different from and not directly comparable to the measures presented by other companies.
Labcorp Holdings Inc. published this content on September 22, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on September 22, 2026 at 20:44 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]